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Edward Chia-Cheng Lai11 , Swu-Jane Lin12 ,
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Sciences, Tzu Chi University, Hualien, Taiwan, 4 Department of Clinical Neurological Sciences,
Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, 5 Heart
and Brain Laboratory, Western University, London, ON, Canada, 6 Department of Epidemiology
and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, ON,
Canada, 7 Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry,
Western University, London, ON, Canada, 8 Department of Family Medicine, Hualien Tzu Chi
Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, 9 Department of Medical Research,
Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, 10 Department
of Neurology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan,
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Medicine, National Cheng Kung University, Tainan, Taiwan, 12 Department of Pharmacy Systems,
Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL,
United States, 13 Department of Neurology, Tainan Sin Lau Hospital, Tainan, Taiwan

Background: Atrial fibrillation detected after stroke (AFDAS) has a lower
risk of ischemic stroke recurrence than known atrial fibrillation (KAF). While
the benefit of oral anticoagulants (OAC) for preventing ischemic stroke
recurrence in KAF is well established, their role in patients with AFDAS is
more controversial. This study aimed to evaluate the association between
OAC use and the risk of recurrent ischemic stroke in patients with AFDAS in a
real-world setting.
Methods: This nationwide retrospective cohort study was conducted
using the Taiwan National Health Insurance Research Database. Patients
hospitalized with a first-ever ischemic stroke and AFDAS confirmed within
30 days after hospitalization were assigned to OAC and non-OAC cohorts.
Inverse probability of treatment weighting was applied to balance the baseline
characteristics of the cohorts. The primary outcome was ischemic stroke
recurrence. Secondary outcomes were intracranial hemorrhage (ICH), death,
and the composite outcome of “ischemic stroke recurrence, ICH, or death.”
Multivariate Cox proportional hazard models were used to estimate adjusted
hazard ratios (aHR) and 95% confidence intervals (CI).
Results: A total of 4,508 hospitalized patients with stroke and AFDAS were
identified. Based on OAC use, 2,856 and 1,652 patients were assigned to the
OAC and non-OAC groups, respectively. During the follow-up period (median
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duration, 2.76 years), the OAC cohort exhibited a lower risk of ischemic stroke
recurrence (aHR, 0.84; 95% CI, 0.70–0.99), death (aHR, 0.65; 95% CI, 0.58–
0.73), and composite outcome (aHR, 0.70; 95% CI, 0.63–0.78) than did the
non-OAC cohort. The risk of ICH (aHR, 0.96; 95% CI, 0.62–1.50) was not
significantly different between the two cohorts.
Conclusion: OAC use in patients with AFDAS was associated with reduced risk
of ischemic stroke recurrence, without an increased risk of ICH. This supports
current guidelines recommending OACs for secondary stroke prevention in
patients with AF, regardless of the time of diagnosis.
KEYWORDS

atrial fibrillation, atrial fibrillation detected after stroke, anticoagulant, ischemic
stroke, intracranial hemorrhage

Introduction

Materials and methods

Stroke can be the initial clinical manifestation of previously
undetected atrial fibrillation (AF) (1). Up to 58.7% of patients
with AF-related acute ischemic stroke have AF detected after
stroke (AFDAS) (2, 3). The prognosis and management of
stroke patients with AFDAS have recently attracted more
attention (3–9) owing to the increased utilization of advanced
monitoring technology for AF screening after a stroke (10, 11).
According to current guidelines (9, 12), newly detected AF in
patients who suffered a stroke should prompt anticoagulation
unless contraindicated. However, compared to patients with
AF known before stroke (KAF), AFDAS seems to have
a more benign profile (5, 6, 8, 13). A recent systematic
review and meta-analysis showed that patients with AFDAS
have a lower burden of risk factors, a lower CHA2 DS2 VASc score, a smaller left atrium, and 26% lower risk of
stroke recurrence than patients with KAF (14). Furthermore,
another systematic review and meta-analysis of randomized
controlled trials has shown that although prolonged cardiac
monitoring in patients with stroke results increased AF
detection and use of oral anticoagulants (OACs), it is not
associated with reduced risk of stroke recurrence (15). These
recent studies suggest that given the relatively benign risk
profile of AFDAS, the use of OACs in these patients may
not be as beneficial as it is for patients with KAF. However,
to our knowledge, no prior randomized controlled trials or
observational studies have confirmed the benefits of OACs
in patients with AFDAS (16). Therefore, we conducted this
nationwide population-based cohort study to examine the
association between OAC use and ischemic stroke recurrence, as
well as with intracranial hemorrhage (ICH) and death, in stroke
patients with AFDAS.

Data sources

Frontiers in Cardiovascular Medicine

The present study was conducted using data from Taiwan’s
National Health Insurance Research Database (NHIRD)
between 2000 and 2018. The NHIRD is derived from the
electronic claims data of Taiwan’s National Health Insurance
program, which enrolls more than 99% of the Taiwanese
population (approximately 23.6 million). The NHIRD is
currently stored and managed by the Health and Welfare Data
Science Center of Taiwan’s Ministry of Health and Welfare (17).
It provides comprehensive healthcare information, including
medication prescriptions, medical device usage, and emergency,
inpatient, or outpatient visits. Information on individual
beneficiaries can be linked and longitudinally followed using
an encrypted identification number. The study protocol was
approved by the Institutional Review Board of Hualien Tzu
Chi Hospital (IRB-107-152C). The requirement for obtaining
informed consent was waived, as personal identifiers of patients
were encrypted in the NHIRD.

Study design, population, and
definitions
In this retrospective cohort study, we identified consecutive
adult patients hospitalized due to first-ever ischemic stroke with
AFDAS between 2012 and 2017 (Figure 1). Each patient’s index
date and year were defined as the admission date and year
of the index stroke event, respectively. Ischemic stroke was
defined based on ICD-9-CM codes 433 and 434 before 2016,
and ICD-10-CM code I63 thereafter (18–20). ICH was defined
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FIGURE 1

Study design. AFDAS, atrial fibrillation detected after stroke; Hosp, hospitalization; X, prescription of oral anticoagulant; Adm, admission; Dis,
discharge; OAC, oral anticoagulant; IS Recur, ischemic stroke recurrence; ICH, intracranial hemorrhage.

also excluded patients who died or had new ischemic stroke
or ICH within 30 days after the index date, prolonged
hospitalization beyond 30 days, or age younger than 20 years
(Supplementary Figure 1).

by applying ICD-9-CM codes 430, 431, and 432 before 2016
and ICD-10-CM codes I60, I61, and I62 thereafter (21). Only
patients with available brain imaging during hospitalization for
their index stroke event were included.
We established a 10-year lookback window to identify and
exclude patients with a previous diagnosis of stroke or related
cerebral vascular disease (ICD-9-CM codes 430–438 or ICD-10CM codes I60–I69), in either inpatient and outpatient claims,
to avoid reporting bias based on outcomes and indication
bias based on anticoagulant use. AF was identified by using
ICD-9-CM codes 427.31 and ICD-10-CM code I48.0–I48.2 or
I48.9 (22, 23). AFDAS was defined as a new diagnosis of AF
in either the inpatient or outpatient claims within 30 days
after the index date. For this purpose, we applied the same
10-year look-back window before the index date to exclude
patients with a previous diagnosis of AF. In Taiwan, prolonged
cardiac monitoring is not reimbursed by the National Health
Insurance, so the vast majority of the AFDAS diagnoses are
made on admission electrocardiography (ECG) or 24-h Holter.
The diagnostic codes for ischemic stroke (18–20) and AF (22,
23) have been previously validated In Taiwan’s NHIRD.
We excluded patients with a previous diagnosis of severe
valvular heart disease such as rheumatic heart disease (ICD-9CM codes 393–398 or ICD-10-CM codes I00-I09), congenital
heart disease (ICD-9-CM codes 746–747 or ICD-10-CM codes
Q20-Q28), or those who had undergone valvular replacement
surgery (NHI procedure code: 68016B, 68017B, 68018B). We
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Allocation of cohorts
The OAC cohort consisted of patients with first-ever
ischemic stroke with AFDAS who received OACs within 30 days
following the index date. The non-OAC cohort consisted of
patients with AFDAS who never received OACs during the same
30-day period (Figure 1).

Covariates
The baseline characteristics of both cohorts were listed
in Table 1. The monthly income was defined based on
the insurance premium, which was income-dependent and
recorded on a graduated scale. It was categorized as dependent,
USD 567–1,076, USD 1,077–1,615, and > USD 1,615.
Comorbidities were defined as diagnostic codes recorded in
at least one inpatient diagnosis or at least two outpatient
diagnoses within 1 year before the index stroke event (23). These
variables were also used to calculate the pre-stroke CHA2 DS2 VASc scores (24). The timing of AFDAS was categorized as
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TABLE 1 Baseline characteristics before and after IPTW.

Original cohorts

IPTW cohorts

OAC
N = 2,856

Non-OAC
N = 1,652

SMD

OAC
N = 2,496

Non-OAC
N = 1,434

SMD

Age, years *

71.7 (11.7)

75.2 (11.9)

0.298

72.5 (10.8)

73.9 (11.2)

0.123

< 65

762 (26.7)

330 (20.0)

0.159

598 (24.0)

325 (22.7)

0.030

65–75

823 (28.8)

386 (23.4)

0.124

739 (29.6)

371 (25.9)

0.083

≥ 75

1,271 (44.5)

936 (56.7)

0.245

1,160 (46.5)

738 (51.4)

0.100

Male

1,680 (58.8)

863 (52.2)

0.133

1,433 (57.4)

790 (55.1)

0.047

Female

1,176 (41.2)

789 (47.8)

0.133

1,063 (42.6)

644 (44.9)

0.047

2012

389 (13.6)

331 (20.0)

0.172

363 (14.6)

245 (17.1)

0.070

2013

396 (13.9)

318 (19.3)

0.145

379 (15.2)

237 (16.5)

0.036

2014

454 (15.9)

308 (18.6)

0.073

427 (17.1)

264 (18.4)

0.035

2015

524 (18.4)

273 (16.5)

0.048

469 (18.8)

271 (18.9)

0.002

2016

541 (18.9)

208 (12.6)

0.175

424 (17.0)

204 (14.2)

0.076

2017

552 (19.3)

214 (13.0)

0.174

433 (17.4)

213 (14.8)

0.069

Dependent

762 (26.7)

468 (28.3)

0.037

676 (27.1)

403 (28.1)

0.023

567–1,076

1,364 (47.8)

853 (51.6)

0.077

1,229 (49.2)

728 (50.7)

0.030

1,077–1,615

373 (13.1)

187 (11.3)

0.053

323 (12.9)

170 (11.9)

0.032

> 1,615

357 (12.5)

144 (8.7)

0.123

268 (10.8)

133 (9.3)

0.049

Age

Sex

Index year†

Monthly income (USD)‡

Comorbidities
Hypertension

1,513 (53.0)

919 (55.6)

0.053

1,334 (53.4)

775 (54.1)

0.013

Diabetes mellitus

580 (20.3)

349 (21.1)

0.020

514 (20.6)

300 (20.9)

0.008

Dyslipidemia

576 (20.2)

296 (17.9)

0.057

497 (19.9)

264 (18.4)

0.038

CAD

476 (16.7)

282 (17.1)

0.011

406 (16.3)

236 (16.4)

0.004

CHF

79 (2.8)

25 (1.5)

0.087

51 (2.0)

22 (1.6)

0.037

MI

37 (1.3)

38 (2.3)

0.075

28 (1.1)

24 (1.6)

0.044

Pre-stroke CHA2 DS2

-VASc score§

Score*

2.4 (1.4)

2.7 (1.4)

0.217

2.5 (1.4)

2.6 (1.4)

0.082

Low risk‡

394 (13.8)

168 (10.2)

0.112

300 (12.0)

166 (11.6)

0.013

Intermediate risk

560 (19.6)

244 (14.8)

0.129

483 (19.3)

253 (17.6)

0.045

1,902 (66.6)

1,240 (75.1)

0.187

1,713 (68.6)

1,016 (70.8)

0.047

2,541 (89.0)

1,427 (86.4)

0.079

2,219 (88.9)

1,264 (88.2)

0.024

315 (11.0)

225 (13.6)

0.079

277 (11.1)

170 (11.8)

0.024

High risk
Timing of AFDAS diagnosis
Inpatient
Outpatient
Stroke severity||
eNIHSS*

9.0 (6.1)

10.9 (7.1)

0.289

9.1 (6.0)

9.9 (6.6)

0.128

1,525 (53.4)

741 (44.9)

0.172

1,297 (52.0)

718 (50.1)

0.038

Moderate

666 (23.3)

319 (19.3)

0.098

606 (24.3)

290 (20.2)

0.098

Severe

665 (23.3)

592 (35.8)

0.278

593 (23.8)

427 (29.8)

0.136

11.6 (7.5)

12.3 (8.0)

0.091

11.6 (7.4)

12.0 (7.9)

0.060

2,517 (88.1)

1,348 (81.6)

0.183

2,208 (88.5)

1,228 (85.6)

0.086

339 (11.9)

304 (18.4)

0.183

288 (11.5)

207 (14.4)

0.086

Mild§

Length of hospitalization
Days*
Physician specialty
Neurology
Others

(Continued)
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TABLE 1 (Continued)
Original cohorts

IPTW cohorts

OAC

Non-OAC

N = 2,856

N = 1,652

SMD

OAC

Non-OAC

N = 2,496

N = 1,434

SMD

Hospital level
Tertiary center

1,179 (41.3)

554 (33.5)

0.160

980 (39.3)

518 (36.1)

0.065

others

1,677 (58.7)

1,098 (66.5)

0.160

1,516 (60.7)

916 (63.9)

0.065

NOAC

1,855 (65.0)

n/a

n/a

1,585 (63.5)

n/a

n/a

Warfarin

1,001 (35.1)

n/a

n/a

912 (36.5)

n/a

n/a

Yes

1,687 (59.1)

1,055 (63.9)

0.099

1,492 (59.8)

939 (65.4)

0.117

No

1,169 (40.9)

597 (36.1)

0.099

1,004 (40.2)

496 (34.6)

0.117

0.118

1,055 (42.3)

565 (39.4)

0.059

1,441 (57.7)

869 (60.6)

0.059

Anticoagulant type

Antiplatelet use

24-h Holter monitoring
Yes

1,226 (42.9)

614 (37.2)

No

1,630 (57.1)

1,038 (62.8)

Data are expressed as n (%) unless otherwise indicated.
*Expressed as mean (SD).
† Index year: the year of admission for the index stroke event.
‡ 1 NTD = 0.036 USD as of Nov 2021.
§ CHA DS -VASc score: low stroke risk was defined as a score of 1 or 0 for women and 0 for men; intermediate stroke risk was defined as a score of 2 for women and 1 for men; high
2
2
stroke risk was defined as a score of ≥ 3 for women and ≥ 2 for men.
|| Severity of stroke: mild severity was defined as a score of ≤ 5; moderate severity was defined as a score of ≥ 6 and ≤ 13; severe severity was defined as a score of > 13.
AFDAS, atrial fibrillation detected after stroke; CAD, coronary artery disease; CHF, congestive heart failure; eNIHSS, estimated National Institutes of Health Stroke Scale; IPTW, inverse
probability of treatment weighting; MI, myocardial infarction; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; SMD, standardized mean difference.

The primary outcome was ischemic stroke recurrence,
defined as an inpatient diagnosis of ischemic stroke after
an examination of brain imaging. The secondary outcomes
included ICH, death, and a composite endpoint of “ischemic
stroke recurrence, ICH, or death.” Death was defined by using
the National Death Registry, linked to the Taiwan’s NHIRD (30).

during the inpatient (before discharge) or the outpatient period
(after discharge). Stroke severity was determined using a claimsbased stroke severity index, which was further transformed
to the estimated National Institutes of Health Stroke Scale
(eNIHSS) score (25). We categorized the eNIHSS as mild (≤ 5),
moderate (≥ 6 and ≤ 13), and severe (> 13) (26, 27). Other
important covariates regarding the index stroke included length
of hospitalization, physician specialty (neurology or others), and
hospital level (tertiary referral center or others). To investigate
anticoagulant use in the OAC cohort, we further classified
patients into those treated with non-vitamin K antagonist oral
anticoagulants for ≥ 1 day within the 30 days following the
index date, and the others were defined as being treated with
warfarin. Antiplatelet use was defined as the use of antiplatelet
therapy for ≥ 1 day within the 30 days following the index
date. 24-h Holter monitoring was defined as whether the
patients received 24-h Holter monitoring within the 30 days
following the index date.

Statistical analysis
Categorical variables were expressed as counts and
percentages, while continuous variables were expressed
as means and standard deviations (SD). To minimize the
selection bias inherent to a non-randomized controlled study,
we used propensity score (PS) matching with a stabilized
IPTW approach to create more homogeneous OAC and
non-OAC groups with balanced baseline characteristics to
facilitate comparisons. We calculated the PS using the logistic
regression model and including covariates of age, sex, monthly
premium level, pre-stroke CHA2DS2-VASc score, timing
of AFDAS diagnosis, eNIHSS, length of hospitalization,
physician specialty, hospital level, and comorbidities (listed
in Table 1). The weights for the stabilized IPTW approach
were defined as Z/PS for OAC group and (1-Z)/(1-PS) for the
non-OAC group. Z and 1-Z were the marginal prevalence of
OAC and non-OAC in the overall population, respectively.
To avoid extreme weights, we removed patients whose PS

Follow-up and outcomes
The date of follow-up onset was defined as 30 days after
the index date (Figure 1). This approach has been previously
used (28) to avoid immortal time bias (29). That is, patients in
both OAC and non-OAC cohorts have to survive up to the same
starting time point to be included in the analysis of outcomes.
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were < 5% or > 95% of the population. Using PS with the
stabilized IPTW approach could generate two interchangeable
groups with the same treatment assignment probabilities,
thus allowing for comparisons based on the average treatment
effects of the entire population (31). Standardized mean
differences were used to determine differences in baseline
characteristics between the two cohorts, and a value of < 0.1
was considered no difference.
The probability of ischemic stroke event-free was
estimated using the Kaplan-Meier method, and the
difference between the event-free curves was examined
using the log-rank test. The association between OAC use
and primary and secondary outcomes was evaluated by
applying multivariate Cox proportional hazard models
and reported as hazard ratios (HR) and 95% confidence
intervals (CI) (32). Multivariate models were adjusted for
age, sex, income, comorbidities listed in Table 1, prestroke CHA2 DS2 -VASc score, timing of AFDAS diagnosis,
eNIHSS, length of hospitalization, specialty of the treating
physician (neurology or others), and hospital level (tertiary
center or others).
Two sensitivity analyses were performed. First, a timevarying analysis was performed to account for crossovers
in treatment groups during follow-up. Second, the Fine
and Gray competing risk model was applied to account for
the competing risk of ICH and death (33). Additionally,
stratified analyses for age, sex, pre-stroke CHA2 DS2 -VASc
score, timing of AFDAS diagnosis, eNIHSS, physician
specialty, or hospital level were performed to estimate
their interaction with the association between OAC use
and the primary outcome. Statistical significance was
defined as a two-tailed probability value of < 0.05. All
statistical analyses were performed using SAS version 9.4 (SAS
Institute Inc., Cary, NC) and Stata version 14.0 (StataCorp,
College Station, TX).

Primary and secondary outcomes in
IPTW cohorts
In the non-adjusted analysis, the risk of ischemic stroke
recurrence was lower in the OAC cohort than in the nonOAC cohort (log-rank test, p = 0.018; Figure 2). At a median
follow-up of 2.76 and 2.53 years, respectively (Table 2), the
numbers (annualized event rates) of ischemic stroke recurrences
in the OAC and non-OAC cohorts were 321 (4.29%) and 209
(5.33%), respectively. The univariate Cox proportion hazard
model indicated a significantly lower risk of ischemic stroke
recurrence in the OAC cohort than in the non-OAC cohort (HR,
0.81; 95% CI, 0.69–0.97; p = 0.018). This association remained
significant in the multivariate model (adjusted HR, 0.84; 95%
CI, 0.70–0.99; p = 0.042) (Table 2). Patients in the OAC cohort
had a similar risk of ICH (adjusted HR, 0.96; 95% CI, 0.62–1.50;
p = 0.864), and had a lower risk of death (adjusted HR, 0.65; 95%
CI 0.58–0.73; p < 0.001) and the composite outcome (adjusted
HR, 0.70; 95% CI, 0.63–0.78; p < 0.001), compared to patients
in the non-OAC cohort.

Sensitivity analyses
In the time-varying sensitivity analysis accounting for
treatment group crossovers, OAC use was associated with a
nearly 50% lower risk of ischemic stroke recurrence (adjusted
HR, 0.52; 95% CI, 0.43–0.63; p < 0.001) (Table 3). In Fine and
Gray’s competing risk model, OAC use was also associated with
a similar trend of lower risk of stroke recurrence compared
with non-OAC use (adjusted HR, 0.91; 95% CI, 0.76–1.06;
p = 0.305) (Table 3).

Stratified analysis
In stratified analysis, there was no significant interaction for
age, sex, pre-stroke CHA2 DS2 -VASc score, timing of AFDAS
diagnosis, 24-h Holter monitoring, eNIHSS, physician specialty,
or hospital level with the association between OAC and stroke
recurrence (Supplementary Table 1).

Results
Baseline characteristics
A total of 4,508 hospitalized patients with both stroke and
AFDAS were identified. Based on OAC use, 2,856 and 1,652
patients were assigned to the OAC and non-OAC groups,
respectively. Patients in the OAC group tended to be younger,
to have higher incomes and lower pre-stroke CHA2 DS2 -VASc
and eNIHSS scores, and were more likely to be male, and to
receive medical care from a neurologist or at a tertiary center
(Table 1). In the IPTW cohorts, the baseline characteristics were
well balanced between the two groups, except that the OAC
group tended to be younger, had lower eNIHSS scores, and
lower proportions of severe stroke, antiplatelet use than did
the non-OAC group.

Frontiers in Cardiovascular Medicine

Discussion
In this large population-based retrospective cohort study,
the use of OACs in patients with first-ever ischemic stroke and
AFDAS was associated with a 16% lower risk of ischemic stroke
recurrence during a median follow-up of 2.76 years. Results were
consistent in sensitivity analyses accounting for treatment group
crossovers and the compering risk of ICH and death. There were
no differences in the risk of ICH between treatment groups.
There were no significant interactions identified for age, sex,
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FIGURE 2

Kaplan–Meier curves for ischemic stroke event-free probability in the OAC and non-OAC cohorts among patients with AFDAS. AFDAS, atrial
fibrillation detected after stroke; OAC, oral anticoagulant.

TABLE 2 Risk of ischemic stroke and secondary outcomes in IPTW cohorts.

Event

FU*

AER†

Multivariate model‡

Univariate model
HR

95% CI

p

0.81

0.69–0.97

0.018

aHR

95% CI

p

0.84

0.70–0.99

0.042

0.96

0.62–1.50

0.864

0.65

0.58–0.73

<0.001

0.70

0.63–0.78

<0.001

Ischemic stroke
OAC

321

2.76

4.29

Non-OAC

209

2.53

5.33

Ref.

Intracranial hemorrhage
OAC

55

2.76

0.73

Non-OAC

30

2.53

0.76

OAC

600

3.11

7.29

Non-OAC

557

2.84

12.90

0.96

0.62–1.49

0.861
Ref.

Death
0.57

0.51–0.64

<0.001
Ref.

Composite outcome§
OAC

825

2.76

11.02

Non-OAC

680

2.53

17.29

0.64

0.58–0.71

<0.001
Ref.

*Expressed as median duration of follow-up (years).
† Expressed as annualized event rate (%).
‡ Hazard ratios were calculated using multivariate Cox regression models with adjustment for age, sex, index year, monthly income, comorbidities listed in Table 1, pre-stroke CHA DS 2
2
VASc score, diagnosis of AFDAS, eNIHSS score, length of hospitalization, physician specialty, and hospital level.
§ Composite outcome defined as development of ischemic stroke, intracranial hemorrhage, or mortality.
aHR, adjusted hazard ratio; AER: annualized event rate; CI, confidence interval; eNIHSS, estimated National Institutes of Health Stroke Scale; FU, follow-up; HR, hazard ratio; IPTW,
inverse probability of treatment weighting; IR, incidence rate; OAC, oral anticoagulant.

CHA2 DS2 -VASc score, timing of AFDAS diagnosis, 24-h Holter
monitoring, eNIHSS, physician specialty, or hospital level.
Currently, major guidelines suggest the use of OAC in
patients with stroke and AF, without differentiating between

Frontiers in Cardiovascular Medicine

KAF or AFDAS (9, 12). This is mainly based on the fact that
AFDAS is a fairly novel concept (13, 15), and that there have
not been any specific randomized clinical trials of OACs vs.
antiplatelet agents or no antithrombotic therapy in patients
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TABLE 3 Sensitivity analyses in the risk of ischemic stroke
in IPTW cohorts.

Univariate model
HR

95% CI

guidelines and indicates that physicians could prescribe OAC
early with confidence once AFDAS has been confirmed.

Multivariate model

p

aHR†

95% CI

p

<0.001

0.52

0.43–0.63

<0.001

Limitations

Sensitivity analysis A*
OAC

0.55

0.47–0.66

Non-OAC

Ref.

Our study has several limitations. First, the diagnosis of
AFDAS in the present study was mainly based on ECGs at
admission and 24-h Holter monitoring. As such, the results
are not generalizable to patients with AFDAS on prolonged
Holter monitoring or implantable loop recording, who may
have a different (and probably lower) AF burden. Results
are awaited from those ongoing randomized trials, such as
the FIND-AF2 trial (35), which is expected to provide more
definitive information on this subject. Second, the use of a
limited time window (30 days after the index stroke event) to
identify the OAC and non-OAC cohorts is a limitation of the
current study, because there could be cross-overs between the
specified time windows. Third, unmeasured confounders such
as hemorrhagic transformation, the size of cerebral infarctions,
cerebral microbleeds, or comorbidities associated with high
embolic or hemorrhagic risk may have influenced the results.
However, the application of IPTW, as well as the consistency
of the results of multivariate models and sensitivity analyses,
suggest that our results are unlikely to be explained by selection
bias. Fourth, the proportion of severe stroke (eNIHSS > 13)
was higher in the non-OAC group, even after the application
of IPTW. Nevertheless, the p-value for this interaction was
insignificant (p = 0.224) for the severe stroke subgroup
(Supplementary Table 1). Fifth, the use of a 10-year lookback
period to exclude patients with a previous stroke and/or
a previous AF diagnosis may have led to misclassification.
However, this risk might be negligible (5, 36). Sixth, it would
be more accurate to consider a certain proportion of patients
who were re-admitted within the first 30-day period after index
stroke admission as experiencing a continuation of the same
stroke episode, instead of having an early stroke recurrence.
Excluding these patients from the current study may have
caused a selection bias. Lastly, we did not apply a cut-off value
for AF duration for it to be considered as clinically relevant. AF
was identified retrospectively based on claims records (22, 23).
Such AF was likely to be high burden, because it was diagnosed
on admission ECGs or short-term monitoring in usual care;
therefore, it was probably a fairly homogenous group of AFDAS
from a prognostic perspective.

Ref.

Sensitivity analysis B†
OAC
Non-OAC

0.90

0.76–1.07

0.240

Ref.

0.91

0.76–1.09

0.3050

Ref.

*Sensitivity analysis A: we used time-varying analysis to evaluate the effect of OAC on
the primary outcome.
† Sensitivity analysis B: we used the Fine and Gray’s competing risk model to evaluate the
effect of OAC on primary outcome.
aHR, adjusted hazard ratio; CI, confidence interval; HR, hazard ratio; IPTW, inverse
probability of treatment weighting; OAC, oral anticoagulant.

with AFDAS. The results of the present real-world populationbased study represent the closest possible approach to filling this
knowledge gap, since a randomized controlled trial of OACs
would be ethically unfeasible.
It is important to note that not all AFDAS have the same
embolic risk. It has been proposed that AFDAS identified on the
admission ECG or on short-term monitoring (e.g., 24-h Holter)
may entail a higher burden and embolic risk, whereas lowerburden AFDAS detected on prolonged cardiac monitoring (e.g.,
30-day external loop recorders or 2 or 3-year implantable loop
recorders) may lower the risk of stroke recurrence (15). In
the present study, AFDAS was diagnosed on admission with
ECGs or 24-h Holter monitoring within 30 days after stroke
in usual care settings. As a result, most AFDAS may have been
high-burden and may have occurred asymptomatically before
stroke occurrence. Although this assumption is hypothetical,
the likely high-burden nature of most AFDAS in our cohorts
may explain the association between OAC use and lower risk
of stroke recurrence.
In sensitivity analysis, the time-varying analysis accounting
for changes in OAC exposure during the follow-up period
found that there was an even greater risk reduction (nearly
50% reduction in HR, p < 0.001) in ischemic stroke recurrence
than there was in the main analysis (16% reduction, in HR,
p = 0.042). However, this association was not statistically
significant after taking into account the competing risks of
ICH and death using Fine and Gray’s method in sensitivity
analysis (9% reduction in HR, p = 0.305). This highlights the
importance of adherence to OAC treatment for patients with
AFDAS, and this information might provide physicians more
confidence to initiate and maintain OAC treatment for poststroke care in these patients. As only 37.1% and 39.3% of patients
with stroke and newly confirmed AFDAS on serial ECGs or 24-h
Holter monitoring, respectively, were prescribed with OACs at
discharge (34), our real-world evidence lends support to current
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Conclusion
For acute patients with ischemic stroke with AFDAS, OAC
initiation within 30 days after stroke was associated with
a reduced risk of ischemic stroke recurrence but without
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